LRRK2 and Parkinson disease: Importantly, a stearoyl CoA desaturase (SCD) inhibitor, which has been shown to improve αSyn dyshomeostasis in cultured neurons32,33 and mice34 expressing fPD-mutant αSyn, rescued the decreased T:M ratio for both LRRK2 mutations, supporting a common pharmacological treatment for tetramer-abrogating forms of PD.